Bristol Is Confident In Abilify Acceptance By Physicians For Depression
Executive Summary
Acceptance of Bristol-Myers Squibb's Abilify (aripiprazole) as adjunctive therapy for major depressive disorder may be eased by existing off-label use of the atypical antipsychotic in that market, according to the company
You may also be interested in...
Bristol Readies Abilify Sales Force For Major Depressive Disorder Push
Bristol-Myers Squibb has restructured its sales force to support the launch of its atypical antipsychotic Abilify as an adjunct treatment for adults with major depressive disorder, Worldwide Pharmaceuticals Chief Operating Officer Lamberto Andreotti said during the company's 2007 fourth-quarter earnings call Jan. 31
Bristol Readies Abilify Sales Force For Major Depressive Disorder Push
Bristol-Myers Squibb has restructured its sales force to support the launch of its atypical antipsychotic Abilify as an adjunct treatment for adults with major depressive disorder, Worldwide Pharmaceuticals Chief Operating Officer Lamberto Andreotti said during the company's 2007 fourth-quarter earnings call Jan. 31
Bristol Looks To New Abilify Uses But Drops Vinflunine Lead Indication
Bristol is gearing up for new growth for its atypical antipsychotic Abilify (aripiprazole) with a new direct-to-consumer advertising campaign and a series of expanded indications